-+ 0.00%
-+ 0.00%
-+ 0.00%

Zevra Therapeutics Presents Four New Data On MIPLYFFA To Treat Niemann-Pick Disease Type C; Arimoclomol Shown To Be Well-Tolerated

Benzinga·02/04/2026 12:33:06
Listen to the news

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium.